Alphamab Oncology to Present the Latest Clinical Data of Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024

CAR-T Digest - August 2020

12 Aug 2024: Alphamab Oncology to Present the Latest Clinical Data of Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024

Alphamab Oncology will present new data on JSKN003 at the ESMO Congress 2024, focusing on its use in platinum-resistant ovarian cancer and advanced HER2-positive solid tumors
JSKN003 is an anti-HER2 bispecific ADC developed with Alphamab’s Glycan-specific conjugation platform, offering improved serum stability and a stronger bystander effect
Phase I trials in Australia and China have shown that JSKN003 has favorable tolerability, safety, and promising preliminary anti-tumor activity
Ongoing clinical studies include a pivotal trial in China for advanced HER2 low-expression breast cancer
Alphamab Oncology, listed on the Hong Kong Stock Exchange, specializes in developing innovative cancer treatments and has a competitive global pipeline